Elevar Therapeutics

Meet Peter Lu, Director Statistical Programming. His manager, Xianzhang Meng had this to say about him, "Peter is a great Elevarian because he takes initiative and always does his best. He brings energy and works well with others, helping the whole team succeed." #FacesOfElevar #ElevarTx #ElevarTherapeutics #ElevarCulture

Today is Cancer Biomarker Awareness Day! Cancer biomarker testing is transforming cancer care by helping ensure patients receive the most effective treatments based on their tumor’s unique molecular profile. Biomarker testing should happen before treatment decisions are made and again if cancer returns. Clinicians, advocates, patients, and communities all play a role in raising awareness, educating, and advocating for equitable access to testing. Join us in spreading the word and empowering patients to ask for timely testing. At Elevar Therapeutics, we leverage the power of biomarkers to develop targeted cancer treatments. One key area of our focus is on cancers with FGFR2 alterations, which may include fusions/rearrangements, mutations or amplifications found in certain cancers, such as cholangiocarcinoma (bile duct cancer) and gastric cancer. We are developing lirafugratinib, a highly selective oral small molecule inhibitor specifically targeting FGFR2. This precision medicine approach means the drug is designed to work effectively only in patients whose tumors have this specific genetic alteration, potentially offering a more effective treatment option with minimal off-target side effects compared to non-selective inhibitors. The development of such targeted therapies underscores the critical importance of timely biomarker testing to identify eligible patients and guide personalized treatment plans. https://lnkd.in/gvhzgzUd #cancerbiomarkers #cancerbiomarkerday #ElevarTx #ElevarTherapeutics

This November, Elevar Therapeutics recognizes Pancreatic Cancer, Lung Cancer, and Gastric Cancer Awareness Month. This is a time to honor patients, their families, and the healthcare community, while shining a light on the urgent need for new and effective treatment options for these challenging diseases. At Elevar, our mission is to elevate treatment outcomes for patients with limited therapeutic options, and our work in oncology directly addresses the needs within these cancer areas. - Gastric Cancer (Stomach Cancer): Our lead proprietary drug candidate, rivoceranib (apatinib), is a small-molecule tyrosine kinase inhibitor (TKI) that was first approved in China as a monotherapy for advanced gastric cancer. It has also been granted Orphan Drug designation for this indication by the U.S. FDA and the European Commission, underscoring the significant unmet need we are working to address globally. - Lung Cancer & Pancreatic Cancer: While our primary focus areas for current regulatory submissions are hepatocellular carcinoma (HCC) and adenoid cystic carcinoma (ACC), our licensed anti-PD-1 antibody, camrelizumab, has been studied in numerous clinical trials for a broad range of tumors, including non-small cell lung cancer (NSCLC) and gastric cancer. These studies highlight the potential of camrelizumab to impact multiple difficult-to-treat cancers. We are committed to the relentless pursuit of innovative medicines, and we are proud to contribute to ongoing research and development in these vital areas. This month and every month, we stand with the entire cancer community to raise awareness and support those affected by these diseases. #CancerAwarenessMonth #PancreaticCancer #LungCancer #GastricCancer #ElevarTherapeutics #ElevarTx #Oncology

Today, on Veterans Day, the team at Elevar Therapeutics extends our deepest gratitude to all who have served in the armed forces. Our mission is rooted in the promise of improving and extending life for patients with limited therapeutic options. We are reminded of the values of service, sacrifice, and hope that our veterans embody every day. Their unwavering commitment to protecting our freedoms inspires our own dedication to relentlessly pursuing new therapeutic solutions for complex health conditions, particularly in oncology. To our veteran colleagues, patients, caregivers, and all veterans in our communities: thank you for your service and profound contributions. #VeteransDay #ThankYouForYourService #ElevarTx #ElevarTherapeutics #CompanyCulture

Elevar Therapeutics is excited to announce a milestone for the combination therapy of camrelizumab and rivoceranib (from the Phase 3 CARES-310 study). The regimen has been included as a first-line therapy option for patients with advanced liver cancer in the updated 2025 Barcelona Clinic Liver Cancer (BCLC) Global Guidelines. This inclusion underscores the clinical evidence from the CARES-310 trial, which demonstrated a median overall survival of 23.8 months, the longest reported in a global Phase 3 trial for unresectable hepatocellular carcinoma (uHCC). We believe the data consistently showed clinically meaningful survival improvement and a manageable safety profile compared to the previous standard of care, sorafenib. The BCLC guidelines are a globally recognized standard for liver cancer management, and this update reinforces our commitment to providing new, effective treatment options for patients with limited therapeutic choices. This is a pivotal step in our mission to elevate treatment experiences and outcomes for those battling cancer. #LiverCancer #HCC #BCLC2025Guidelines #ElevarTx #ElevarTherapeutics #Camrelizumab #Rivoceranib #Oncology

Kristin Ryan, Pharm.D. is excited to be representing Elevar Therapeutics at The Liver Meeting (AASLD) 2025 in Washington, D.C.! This is the premier global conference for liver disease research and innovation, and she's looking forward to connecting with leading clinicians, researchers, and industry partners to share the latest scientific advancements. Elevar is dedicated to developing novel therapies, particularly for patients with hepatocellular carcinoma (HCC), and this event is a fantastic opportunity to discuss how we can continue to elevate outcomes for patients. #TLM25 #ElevarTx #ElevarTherapeutics #Oncology

In honor of National Family Caregivers Month, Elevar Therapeutics is proud to recognize the quiet heroes who provide essential support to their loved ones every day. This year's theme, "Plug-in to Care," highlights the importance of connection and ensuring caregivers have access to vital support tools and resources. We encourage all caregivers to connect with support networks, prioritize their own well-being, and find strength in community. Join us in celebrating and honoring these remarkable individuals. Your work is seen, valued, and appreciated. #NationalFamilyCaregiversMonth #ElevarTx #ElevarTherapeutics #ElevatingOutcomes

Happy Halloween from Elevar Therapeutics! We hope you have a spooktacular day. #ElevarCulture #HappyHalloween

Many people with liver cancer do not experience symptoms in the early stages, which makes awareness of the signs even more crucial. Early detection can lead to more effective treatment. Common symptoms to look out for can include: - Unintended weight loss - Loss of appetite or feeling full after a small meal - Nausea and vomiting - General weakness and fatigue - Swelling in the abdomen - Yellowing of the skin and eyes (jaundice) - Pain in the upper abdomen near the right shoulder blade If you or a loved one experiences any of these symptoms, talk to a healthcare professional. #LiverCancerAwareness #ElevarTx #ElevarTherapeutics

That's a wrap on an incredible ESMO Congress 2025 in Berlin! A huge thank you to the ESMO - European Society for Medical Oncology for another outstanding event that brought the global oncology community together. Our team was energized by the insightful presentations and collaborative discussions. The dedication to progress and innovation on display this year was inspiring and we are more motivated than ever to continue our work in developing promising therapies for patients in need. Until next time, ESMO! #ESMO25 #ElevarTx #ElevarTherapeutics #CancerResearch #Oncology #Berlin